Potential for Net Benefit Should Guide Preventive Therapy

Circulation

Volumn 135, Issue 7, 2017, Pages 630-632

  Stone, Neil J ^a   Robinson, Jennifer G ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

guideline; low density lipoprotein cholesterol; statin therapy

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANKLE BRACHIAL INDEX; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FOLLOW UP; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MAXIMUM TOLERATED DOSE; MEDICAL SOCIETY; PERSONALIZED MEDICINE; PREMATURITY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SHARED DECISION MAKING; SHORT SURVEY; TREATMENT RESPONSE;

CHOLESTEROL, LDL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 85012920248     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.022147     Document Type: Short Survey

References (5)

1. Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. Eur Heart J. 2015;36:2975-2983. doi: 10. 1093/eurheartj/ ehv340.
2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-S45. doi: 10. 1161/01. cir. 0000437738. 63853. 7a.
3. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68:92-125.
4. Robinson JG. Lower might be better: it matters how you get there, and in whom. Eur Heart J. 2016;37:1380-1383. doi: 10. 1093/ eurheartj/ehw102.
5. Tice JA, Kazi DS, Pearson SD. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: efectiveness and value. JAMA Intern Med. 2016;176:107-108. doi: 10. 1001/jamainternmed. 2015. 7248.